Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen advances Alzheimer's drug to late-stage trial despite disappointing dataPhoto: CNBC

Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

Why this matters for military families

Developments that affect daily life for service members and their families at duty stations worldwide.

Read full article at CNBC

Originally published by CNBC. Summary and curation by DutyStation.ai.

📰 Related Stories

📰 General

Traders think this legacy tech stock is the ultimate quantum play

CNBC29m ago
📰 General

Oura, smart ring maker, confidentially files for IPO

CNBC47m ago
📰 General

Trump postpones AI executive order signing: 'I didn't like certain aspects'

CNBC2h ago
📰 General

Trump administration says new EPA rules will save you money at the supermarket. It's not clear they will

CNBC2h ago
📰 General

Cramer says buy this, sell that — plus, another with 30% upside 'written all over it'

CNBC2h ago
📰 General

Spotify soars 15% after announcing AI music deal with UMG, guidance

CNBC3h ago
← Back to Military News